BioSpace News Archive

Cure Alzheimer’s Fund , a non-profit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease, announced today that it has received a $30,000 grant from the Robert A. Stranahan, Jr. Charitable Advised Fund of the Greater Toledo Community Foundation.

Hologic Ranked #1 for Mammography System Performance and Customer Satisfaction for 10th Consecutive Year.

ReCode Therapeutics announced today the appointment of Patricia “Trisha” Millican to the company’s Board of Directors.

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the results of a new study published in Transplantation Direct1 which establishes a reference baseline when using AlloSure® Lung in the long-term surveillance of lung transplant patients.

InnerScope Hearing Technologies Inc., an emerging and disruptive leader in the Over-the-Counter Hearing Aid space announced that it has launched four models of iHEAR branded Over-the-Counter Rechargeable Hearing Aids on CVS.com.

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Suman M. Verma, M.D., Ph.D., Lucid’s Chief Scientific Officer, presented real-world data on its EsoCheck ® Cell Collection Device (“EsoCheck”) at the American Association for Cancer Research’s (“AACR”) Special Conference.

Surgical Innovation Associates (SIA) today announced that it entered into a definitive agreement to be acquired by Integra LifeSciences Holding Corporation.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that, following the recent receipt of official minutes from its pre-NDA (New Drug Application) meeting with the U.S. Food and Drug Administration (FDA), the Company plans to submit an NDA as soon as the end of 2022 for marketing approval of the investigational drug candidate ADX-2191 for the treatment of primary vitreoretinal lymphoma.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the 2022 San Antonio Breast Cancer Symposium, December 6-10 in San Antonio, Texas.

A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this week, causing a flurry of activity in the markets for the worthy recipients.